Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Hematological toxicity is the most common adverse event after chimeric antigen receptor (CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for severe infectious complications. In a recent worldwide survey, we demonstrated that there remains considerable heterogeneity in regard to current practice patterns. Here, we sought to build consensus on the grading and management of immune effector cell-associated hematotoxicity (ICAHT) after CAR T-cell therapy. For this purpose, a joint effort between the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA) involved an international panel of 36 CAR T-cell experts who met in a series…

• A
  Amgen
• BS
  Bristol-Myers Squibb
• P
  Pfizer
• A
  AstraZeneca
• S
  Sanofi
• GS
  Gilead Sciences
• C
  Celgene
• RP
  Regeneron Pharmaceuticals
• JP
  Jazz Pharmaceuticals
• LL
  Les Laboratories Pierre Fabre
• B
  BeiGene
• I
  Incyte
• C
  Celltrion
• S
  Servier
• M
  Medac
• JP
  Janssen Pharmaceuticals
• DS
  Daiichi Sankyo Europe